G1 Pharma (GTHX) - יחס שווי שוק לערך בספרים

G1 Therapeutics, Inc. (GTHX) is attracting leading biologists for bone marrow protection, which is sparking investor interest. The market capitalization-to-book value ratio illustrates this trend, where 15.19 is the current level of the metric. This is supported by a successful merger with Pharmacosmos under transparent rights and a leadership shift toward a strategy of extracting profit from oncology licensing royalties.

G1 Therapeutics, Inc. (GTHX) focuses on oncology research without burdening its balance sheet with heavy manufacturing capacities. The multiple is calculated as the ratio of the total market capitalization to the value of net assets. This coefficient determines the premium the market is willing to pay for intellectual capital and future patents. The trend of this indicator signals a shift in the phases of how investors value the business. By analyzing the historical changes in the market-to-book capitalization multiple, one can identify a reversal in the fundamental trend.